Compare PXLW & PLUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXLW | PLUR |
|---|---|---|
| Founded | 1997 | 2001 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.1M | 33.9M |
| IPO Year | 2000 | 2001 |
| Metric | PXLW | PLUR |
|---|---|---|
| Price | $6.01 | $3.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $14.33 | $12.00 |
| AVG Volume (30 Days) | ★ 23.9K | 6.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 10.78 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $43,206,000.00 | $1,336,000.00 |
| Revenue This Year | N/A | $97.38 |
| Revenue Next Year | $3.54 | $293.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 309.82 |
| 52 Week Low | $0.46 | $2.82 |
| 52 Week High | $15.42 | $7.13 |
| Indicator | PXLW | PLUR |
|---|---|---|
| Relative Strength Index (RSI) | 45.89 | 44.88 |
| Support Level | $5.67 | $3.13 |
| Resistance Level | $6.77 | $3.42 |
| Average True Range (ATR) | 0.30 | 0.17 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 34.46 | 18.95 |
Pixelworks Inc is a provider of visual processing semiconductor and software solutions that enable consistently high-quality and authentic viewing experiences in a wide variety of applications. The company defines its key target markets as Mobile (smartphone and tablet), Home and Enterprise (projectors, personal video recorders (PVR), and over-the-air (OTA) streaming devices), and Cinema (creation, remastering, and delivery of digital video content). The company operates in one segment: the design, development, marketing and sale of IC solutions for use in electronic display devices. The company generates its revenue from two broad product markets: the Mobile market and the Home and Enterprise market. The majority of the revenue is earned in Japan.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.